TScan Therapeutics (NASDAQ:TCRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
TScan Therapeutics beat estimated earnings by 46.67%, reporting an EPS of $-0.24 versus an estimate of $-0.45.
Revenue was up $524 thousand from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.27 which was followed by a 1.9% drop in the share price the next day.
Here’s a look at TScan Therapeutics’s past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.78 | -0.74 | -0.70 | -0.72 |
| EPS Actual | -0.51 | -0.93 | -0.78 | -0.67 |
| Revenue Estimate | 4.03M | 4.40M | 3.82M | 3.70M |
| Revenue Actual | 3.15M | 6.80M | 3.10M | 3.36M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for TScan Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
